Zoliflodacin Shows Efficacy Against Gonorrhea Even with Chlamydia Co-infection

New data presented at IDWeek 2026 indicates that zoliflodacin, a single-dose oral antibiotic for uncomplicated urogenital gonorrhea, maintains high cure rates even when patients are co-infected with Chlamydia trachomatis. The findings suggest that concurrent chlamydial infection does not compromise zoliflodacin's effectiveness against Neisseria gonorrhoeae. Clinicians are advised to continue independent diagnosis and management of chlamydial infections.